Phase II study of MLN518 in patients with metastatic clear cell renal cell carcinoma
Phase of Trial: Phase II
Latest Information Update: 24 Nov 2017
At a glance
- Drugs Tandutinib (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 24 Mar 2010 Actual patient number (10) added as reported by ClinicalTrials.gov.
- 28 Oct 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.